Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor
Filing based on unprecedented data package that met all primary endpoints across four Phase 3 studies, including head-to-head superiority comparisons versus deucravacitinib and evaluation of difficult to treat skin sites
Submission underscores potential to offer moderate-to-severe plaque psoriasis patients the standout combination of complete skin clearance, favorable safety profile, and simplicity of a once-daily pill
Read More
Preliminary evaluation confirms low-cost pathway to production
HIGHLIGHTS
Capital cost for full reinstatement of Central Gawler Mill to original design basis (600ktpa fresh ore) estimated at only ~A$26m (±30%); processing cost estimated at only A$44.50/t
Significant cost advantages versus building a new mill, or utilising third party toll milling
Targeting feasibility by end of 2025 to support initial ‘Stage 1' operations by end of 2026; early conversations underway for low-dilution credit and working capital financing
As thousands suffer without access to FDA-approved cannabis treatments, MMJ BioPharma Cultivation is waging a David vs. Goliath legal war against the DEA's decade-long deception-and incoming Administrator Terrance Cole must decide whether to continue the cover-up or finally put patients over politics.
Read More
In a bold move that bridges the worlds of high-stakes poker and high-impact social innovation, AngelAi partnered with Michael "The Grinder" Mizrachi, who had a historic victory at the 2025 World Series of Poker (WSOP) Main Event on Wednesday, where he claimed the coveted World title, a $10 million prize and entry into the hall of fame.
Read More
News Release Highlights:
Battery X Metals Inc.'s wholly-owned subsidiary, Battery X Rebalancing Technologies Inc., has entered into a Commercial Revenue Share Agreement with an arm's length, independent Vancouver-based automotive service center specializing in out-of-warranty Tesla vehicles. The agreement marks the first commercial deployment of its patent-pending, second-generation lithium-ion battery rebalancing machine ("Prototype 2.0") in a live customer-facing environment.
Under the terms of the Agreement, Battery X Rebalancing Technologies will receive 20% of gross service revenue per rebalancing procedure, plus applicable taxes, with no direct costs incurred for labor, overhead, or shop operations-establishing a potential early-stage revenue stream with no direct operating expenses.
The Revenue Share Agreement follows a successful real-world performance trial in which Prototype 2.0 restored a severely imbalanced light-duty electric truck's estimated driving range from approximately 40 kilometers to 295 kilometers-a 255-kilometer increase representing a 637.5% improvement-validating the commercial potential of the platform.
RLTR becomes top-performing AI stock of the week, surpassing tech heavyweights Microsoft (MSFT), NVIDIA (NVDA), Alphabet (GOOGL), Amazon (AMZN), Meta (META), AMD, and Palantir (PLTR),
Read More
